Efficacy of switching to Basal-supported GLP-1RA therapy(BGT) in type 2 diabetes patients treated with multiple daily insulin injections

Efficacy of switching to Basal-supported GLP-1RA therapy(BGT) in type 2 diabetes patients treated with multiple daily insulin injections - Efficacy of BGT in type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021693

Enrollment

Registered

2016-03-30

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A type 2 diabetes patient treated with multiple daily insulin injections, whose HbA1c level > 8.0%.

Exclusion criteria

Exclusion criteria: Type 1 diabetes; Suspicios for type 1 diabetes because of positiveness of GAD, IA-2 or ZnT8 antibodies in their sera; Serum C-peptide level < 0.6 ng/ml; Other type diabetes(Seconday diabetes, Steroid induced diabetes, ect.); Pregnant women

Design outcomes

Primary

Measure	Time frame
We judge the case that the period when HbA1c < 7.0% was able to maintain it came across more than six months with a BGT effective case.	—

Countries

Japan

Contacts

Public ContactIchiro Horie

Nagasaki Univ. Hospital Endocrinology and Metabolism

holy197741@me.com0958197262

Outcome results